During the ongoing COVID-19 era, studies by Global Fund have demonstrated that pandemic response measures such as lockdowns had reduced access to key health services like TB diagnosis and treatment. Globally, COVID-19 led to a 29% decline in the TB detection rates in 2020 as current studies noted [1]. During pandemic lockdowns, reduction of sputum sample obtained for TB diagnosis due to people shunning health facilities and health workers prioritising COVID-19 over other conditions [2]. Country level declines for TB notifications ranged from 41% in South Africa to 25% in India, highlighting major disruptions in high TB burden countries [3]. However, prior to COVID-19 already, the African region had 17 countries, which have the highest burden of TB. New TB diagnosis notifications and screening programs declined in part due to a reduction in numbers of health workers, limited access to facilities, and data reporting lapses thus affecting treatment access. The World Health Organisation (WHO) states that in 2020, of the 10 million people who developed TB, only 5.8 million cases were detected globally, leaving 4.2 million undetected and a pool for further transmission in communities [4]. These cases of undetected TB are expected to continue to rise soon. In addition, the number of people dying from TB increased both among HIV negative (from 1.2 million in 2019 to 1.3 million in 2020) and among HIV positive individuals (from 209,000 in 2019 to 214,000 in 2020) [4].
The underlying determinants of TB are poverty, undernutrition and stress and numbers of TB cases will rise further in Africa while untreated TB could kill more than half of those with disease [5]. Additionally, TB/COVID-19 coinfection appears to triple mortality compared with TB mono infection [6, 7]. The impoverished and malnourished are likely to have undiagnosed TB because of health services disruptions and stigma due to COVID-19, this has further led to an increase in TB incidence and mortality which is disproportionately higher among the low-income communities [8]. Larger cross-continental studies are required to define accurately the trends of undiagnosed and new TB cases, MDR-/XDR-TB and impact of TB/COVID-19 co-infections on management outcomes. Associated risk factors for mortality also need to be defined [8]. The disruptions to pharmaceutical supply chains and national TB programs require urgent attention as indicated by Inzaule et al. [9].
Tuberculosis (TB) has been the leading infectious cause of death among people living with HIV (PLWH), causing one third of AIDS-related deaths globally. The End TB strategy launched by the United Nations Political Declaration on Ending AIDS in 2016, aimed at achieving 75% reduction of TB-related AIDS deaths by 2020 [10]. Additionally, the WHO End TB strategy aimed to initiate TB therapy in 90% of all people who require it, including those at higher risk, deprived and achieve at least 90% treatment success by 2030 [10, 11]. While TB incidence has been declining, incidence rates will still be 1000 times greater than the desired elimination threshold if current rates of decline remain unchanged [12]. This slow progress has in part been due to quality gaps in TB and HIV services across the cascade of care, with suboptimal uptake of interventions, especially TB diagnosis in patients with advanced HIV disease, molecular diagnostic platforms such as Xpert MTB/RIF, lack of access to optimal TB prevention and treatment regimens, infrastructure, supply of drugs, diagnostics and BCG vaccines, and information systems challenges [13]. These gaps become a barrier towards achieving prevention and treatment targets within the TB-HIV care cascades [14, 15].
TB elimination targets may be achievable through robust implementation strategies aimed at improving quality along the continuum of TB care, through use of new technologies in TB prevention, diagnosis, and treatment [16].
As a response to the relentless TB-HIV co-morbidity, the WHO proposed TB-HIV service integration at least at the facility level. Unfortunately, we still don’t have any consensus with regards to the model of integration and the levels at which integration should occur. Various models (linkage, collaboration, full integration) have been proposed, but each one bearing several challenges across various settings [17]. For instance, in a linkage model, when a patient is diagnosed with either of the two infections, he/she is referred to another facility or unit to be tested for the other. The collaborated model is concerned with the partial integration of services whereby a person who has been diagnosed through TB services will also be counselled and tested for HIV and then referred if positive. In a fully integrated model of care, all services for TB and HIV are provided in a single facility and by the same service providers. An overwhelming body of evidence, however, suggests that the fully integrated option offers optimum benefits for clients, health systems and workers [18, 19].
The quality of integrated TB/HIV care is characterised by the patient-centred approach, uniform with international standards, efficient and effective, equitable, timely, safe and accessible. The framework of universal health coverage emphasizes components of quality care by including patients’ right to care, equitable service delivery and needs based healthcare [17, 18, 19]. Therefore, the quality TB and HIV services include: (i) Screening for HIV and TB with appropriate tests, access to prevention for TB and HIV in those that screen negative, and linkage to appropriate treatment for TB and HIV in those that screen positive; (ii) Effectiveness of care including timely identification of both HIV and TB, linkage to appropriate treatment, continued clinical and laboratory monitoring until favourable outcomes are achieved [19]. Health systems weaknesses and underperformance in healthcare delivery contribute to poor quality TB/HIV care. Health systems failures exist on multiple levels of the health care system, particularly at healthcare worker level, and at management and policy levels. Healthcare workers trainings’ needs for provision of quality care are inadequate because lower numbers of trained health care personnel remain a challenge for TB and HIV programs. In South Africa, provision of TB services has historically been delivered by lower-level staff such as enrolled nurses, and community health workers [22]. Professional nurses, and doctors do not routinely offer TB testing, and treatment services. This creates a challenge especially in disease endemic settings, where skilled staff lack adequate confidence, training, and experience in screening, diagnosing and managing TB and HIV [22].
Integration of tuberculosis and HIV services particularly in resource-limited South African provinces such as the Eastern Cape Province has been far from optimal despite the existence of policy frameworks for integration. Achieving widespread integration of TB-HIV care is still unsatisfactory, regardless of a documented intent towards full integration [17, 18, 19, 20, 21, 22]. While this is not the first empirical discourse on TB-HIV integration in the country, this, to the best of our knowledge, marks the first attempt to investigate operational challenges of TB-HIV integration from the perspectives of service providers and patients at the facility level. We used the “complexity theory” as a theoretical framework able to guide the conduct of this study [23].